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Genetic testing of leukodystrophies 
unraveling extensive heterogeneity 
in a large cohort and report of five 
common diseases and 38 novel 
variants
Nejat Mahdieh1,2, Mahdieh Soveizi2, Ali Reza Tavasoli3, Ali Rabbani1, 
Mahmoud Reza Ashrafi3, Alfried Kohlschütter4 & Bahareh Rabbani1,5*
This study evaluates the genetic spectrum of leukodystrophies and leukoencephalopathies in 
Iran. 152 children, aged from 1 day to 15 years, were genetically tested for leukodystrophies and 
leukoencephalopathies based on clinical and neuroradiological findings from 2016 to 2019. Patients 
with a suggestive specific leukodystrophy, e. g. metachromatic leukodystrophy, Canavan disease, Tay-
Sachs disease were tested for mutations in single genes (108; 71%) while patients with less suggestive 
findings were evaluated by NGS. 108 of 152(71%) had MRI patterns and clinical findings suggestive of 
a known leukodystrophy. In total, 114(75%) affected individuals had (likely) pathogenic variants which 
included 38 novel variants. 35 different types of leukodystrophies and genetic leukoencephalopathies 
were identified. The more common identified disorders included metachromatic leukodystrophy (19 
of 152; 13%), Canavan disease (12; 8%), Tay-Sachs disease (11; 7%), megalencephalic leukodystrophy 
with subcortical cysts (7; 5%), X-linked adrenoleukodystrophy (8; 5%), Pelizaeus–Merzbacher-
like disease type 1 (8; 5%), Sandhoff disease (6; 4%), Krabbe disease (5; 3%), and vanishing white 
matter disease (4; 3%). Whole exome sequencing (WES) revealed 90% leukodystrophies and genetic 
leukoencephalopathies. The total diagnosis rate was 75%. This unique study presents a national 
genetic data of leukodystrophies; it may provide clues to the genetic pool of neighboring countries. 
Patients with clinical and neuroradiological evidence of a genetic leukoencephalopathy should 
undergo a genetic analysis to reach a definitive diagnosis. This will allow a diagnosis at earlier stages 
of the disease, reduce the burden of uncertainty and costs, and will provide the basis for genetic 
counseling and family planning.
Background
Leukodystrophies and genetic leukoencephalopathies are a large heterogeneous group of genetic diseases affect-
ing the white matter of the central nervous system. The single diseases are rare, but overall they affected 1 per 
7663 live births, in a US American  study1; the estimated prevalence of leukodystrophies is about 1–2/100,000 
live births in  Germany2. Most of these diseases are associated with severe progressive functional losses of motor 
and cognitive abilities, helplessness and early death. Their causes are either related to primary defects of myelin 
synthesis and myelin stability, but myelin damage may also be secondary to disturbances outside this  structure3. 
Some mitochondrial and lysosomal storage disorders, organic acidemias, other inborn errors of metabolism and 
vascular disorders are also categorized under genetic  leukoencephalopathies4.
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Leukodystrophies are clinically and genetically heterogeneous disorders; their diagnosis is challenging and 
nearly half of the patients will remain  undiagnosed5, putting a high economical and psychological burden on the 
society and the affected families. Many known genes have been recognized to cause these diseases, though there 
are many with unknown genetic etiology. Advances in gene sequencing procedures and whole exome sequencing 
(WES) unravel the genetic causes of  leukodystrophies6. Genetic testing confirms the diagnosis and may offer a 
chance for disease-specific palliative treatment or experimental therapies of some diseases (e. g. metachromatic 
leukodystrophy (MIM 250100), Alexander disease (MIM 203450), and Krabbe disease (MIM 611722)7,8. In addi-
tion, molecular genetic analysis would help for family screening and reproductive decisions. Most of the pediatric 
disorders follow an autosomal recessive pattern of inheritance and come from consanguineous marriages which 
are prevalent in Iran and the Middle East. Despite advances in molecular technologies and the high frequency 
of genetic diseases in Iran as the crossroads of the Middle East, there is no comprehensive study on genetics of 
pediatric white matter disorders in this region of the world. The genetic composition of different parts of Iran 
could be representative of the respective neighbors.
Here, we have evaluated the genetic spectrum of subjects clinically diagnosed with leukodystrophies referred 
to a tertiary pediatric center in Iran. The purpose of the study was to determine the common types of leukod-
ystrophies and genetic leukoencephalopathies, neurological findings in the patients, and ethnical distribution 
of the disease.
Results
Patients’ demographic data and clinical diagnoses. A total of 152 patients, including 94 (62%) males 
and 58 females, aged from 1 day to 15 years old, has been clinically diagnosed with leukodystrophy or genetic 
leukoencephalopathy. The distribution of the more common referred diseases among the patients was as follows: 
25 patients clinically diagnosed with  MLD9, 13 CD, 10 PMLD, 6 PMD, 2 PMD or PMLD, 12 TSD, 10 X-ALD, 8 
SHS, 8 MLC, 3 AxD, 3 KD, 4 hypomyelination and congenital cataract (HCC; Hypomyelinating Leukodystro-
phy 5; HLD5; MIM 253260), 1 Sialic disease, 1 RNAse T2 deficient leukoencephalopathy (MIM 612951), and 2 
biotinidase deficiency (MIM 253260).
Totally, 108 of 152 patients (71%) had defined MRI patterns (not available) and were clinically diagnosed 
with a known leukodystrophy. Measurements of lysosomal enzymes in MLD, KD, TSD and SHS were performed 
for diagnosis. Urinary sulfatides (for e. g. MLD), plasma very long chain fatty acids (for e. g. X-ALD) were also 
tested to help the diagnosis. These patients were candidates for single gene analysis.
44 of 152 patients (29%) had no definite MRI pattern and no definite biochemical or single gene test could 
be performed for them. They were candidates for panel gene analysis and/or WES.
Demographic, clinical and genetic evaluation of patients confirmed genetically. Thirty-five 
different leukodystrophies and genetic leukoencephalopathies were identified in this study (Table 1). The clini-
cal characteristics of the most common genetically confirmed patients are summarized in Table 1 and Fig. 1A. 
The main clinical manifestation was motor regression and neurological complaints including dystonia, hypoto-
nia, developmental delay, ataxia, tremor, seizure, macrocephaly, nystagmus, cognition and learning impairment 
(Table 1 and Supplementary Table 2).
114 (75%) patients were confirmed based on genetic testing. Male consist of 73 of 114 (64%) of patients. The 
mean age of onset was 5yrs and 1 m ± 18yrs and 11 m. 94 of 114 (82. 5%) cases were born in a consanguineous 
family. The ethnicity of these patients is compared in Fig. 1B. The ethnical distribution showed higher incidence 
in Fars 32%; other ethnical distribution included 27% in Turk, Arab 13%, Lur 8%, Kurd 7%, Mazani 4%, Gilak 
3%, and the rest Balooch, Afghan, Lak, and Turkeman (Fig. 1B). Based on age of onset of disease, 47 infantile 
(41%, I), 17 late infantile (15%, LI), 29 early juvenile (25%, EJ), 19 late juvenile (17%, LJ) and 2 adults (A) were 
available (Supplementary Table 2).
38 of 152 (25%) patients were not genetically confirmed based on genetic analysis. Some candidates of single 
gene analysis were not tested for panel based analysis because the parents were not satisfied for the test perfor-
mance (Fig. 2). In addition, panel negative patients did not perform WES.
Single gene analyses. Sixteen patients had mutations in the ARSA gene (MLD), 8 in ABCD1 gene 
(X-ALD), 12 in ASPA gene (CD), 3 in GALC (GLB), 7 in MLC1 gene (MLC), 1 in GFAP gene, 1 in PLP1 gene 
(PMD), 6 in GJC2 gene (PMLD), 11 in HEXA, 5 in HEXB, 2 in L2HGDH, 1 in BTD and 1 in SCL17A5 gene 
(Table 1). Totally, 74 out of 108 (69%) patients were genetically diagnosed based on single gene analysis (Fig. 2).
Next generation sequencing: gene-panel and WES. Gene-panel and WES identified 40 of 44 (90%) 
patients having leukodystrophies and leukoencephalopathies (Table 1, Supplementary Table 2). Four cases did 
not show any variants with multigene panel analysis of leukodystrophies (Fig. 2).
Frequency of lysosomal, peroxisomal, mitochondrial and errors of intermediary metabo-
lism. Fifty of 114 patients were diagnosed as lysosomal disorders (29 lysosomal LD and 21 lysosomal gLE) 
(Table 1, Fig. 2 and Supplementary Table 2).
Eleven patients were diagnosed as peroxisomal disorders which eight of them were X-ALD (Table 1, Fig. 2 
and Supplementary Table 2).
Forty patients diagnosed as errors of intermediary metabolism, consisted of 12 CD, 8 PMLD and 7 MLC 
(Table 1). CD as the most common degenerative cerebral diseases, due to abnormal amino acid/organic acid 
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No Name of disease
Alternative 
designation, 




1 Metachromatic leu-kodystrophy MLD 250100 ARSA ER, Lysosome 19 (16. 7) 16 3
AG:2, MR:15, DD:2, 
CI:1, speech problem:6
2 Krabbe Disease KD 245200 GALC Lysosome 5 (4. 4) 3 2
Hypotonia:1, speech 
problem: 2, Spasticity: 
2, AG: 2, Seizure: 2, 
MR: 5, DD:2
3 Fucosidosis 230000 FUCA1 Lysosome 2 (1. 8) 0 2
Hypotonia:1, Dental 
germination:1, skin 
lesions:1, AG:1, DD: 2
4 Salla Disease SD 604369 SLC17A5 Lysosomal and cell membrane 1 (0. 9) 1 0
speech problem, 
Seizure, DD, MD
5 Multiple sulfatase deficiency MSD 272200 SUMF1 ER 1 (0. 9) 0 1
dried skin, spasticity, 
incapable to walk and 
talk, R, mental retarda-
tion, coarse facial 
feature
6 RNAse T2 deficiency 612944 RNASET2 ER, Lysosome, Extra-cellular 1 (0. 9) 0 1 Hypotonia, DD
7 X-linked adrenoleu-kodystrophy X-ALD 300100 ABCD1
Membrane of ER, 
Mitochondrion, per-
oxisome and lysosome
8 (7) 8 0
Hypotonia: 2, Vision 
problem: 1, Feeding 
problem: 2, AG: 3, 
Seizure: 2, MR: 2, 
LD:1, CI: 4
8 Rhizomelic chondro-dysplasia punctata RCDP 601757 PEX7 Peroxisome 1 (0. 9) 0 1
coarse facial feature, 
cataract, digestive 
problem, DD, MR
9 Zellweger Spectrum ZS 614883 PEX13 Peroxisome mem-brane 1 (0. 9) 0 1
Hypotonia, Seizure, 
MR, feeding problem




11 Canavan Disease CD 271900 ASPA Nucleus, Cytoplasm 12 (10. 5) 12 0
Hypotonia:8, Nystag-
mus and eye prob-
lem:5, Macrocephaly:9, 
Spasticity:3, Irritable:6, 





PMLD 260600 GJC2 Cell membrane, gap junction 8 (7) 6 2
Hypotonia: 6,Nys-







MLC 604004 MLC1 ER and cell membrane 7 (6. 1) 7 0
Macrocephaly:7, Dys-
tonia: 2, AG: 4, Seizure: 
2, MD:2, MR:5




















3,Tremor: 2, AG: 2, 


















Hypotonia: 2, speech 
problem: 2, Tremor:1, 
ataxia:2, AG: 2, 
Seizure:2, MR:1, DD:1, 
nystagmus:1
16 hypomyelination and congenital cataract HCC 610532 FAM126A Cytosol 1 (0. 9) 0 1 congenital cataract
17 Pelizaeus–Merzbacher disease PMD 312080 PLP1
Cell (myelin) mem-
brane 1 (0. 9) 1 0
MR, Hypotonia, 
nystagmus






INAD 603604 PLA2G6 Peripheral membrane 1 (0. 9) 0 1 Hypotonia, bristling head, Seizure




21 Tay-Sachs Disease TSD 272800 HEXA Lysosome 11 (9. 6) 11 0
Vision problem and 
nystagmus:8, R:6, 
DD:4
22 Sandhoff disease SHS 606873 HEXB Lysosome 6 (5. 3) 5 1 Visual problem:2, Seizure:1, R:4, DD:4
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Thirteen patients diagnosed with mitochondrial genetic leukoencephalopathies (Table 1, Fig. 2 and Sup-
plementary Table 2).
Common variants. Five common diagnosed leukodystrophies accounted for 51% (58 of 114 patients) in 
our studied patients included 19 of 58 (33%) MLD, 12 CD, 11 TSD, 8 X-ALD and 8 PMLD (Fig. 2).
Six common mutations were found including p.Gly311Ser (in 6 MLD patients), c.465 + 1G > A (in 3 MLD 
patients), c.634 + 1G > T (in 6 CD patients), c.237_238insA (in two homozygous and one compound heterozy-
gous CD patients), c.1528C > T (in 4 TSD patients) and c.449_455delTCC TGC T (two homozygous and one 
heterozygous MLC patients).
Novel variants. Thirty-eight novel variants were identified in 40 patients (Table 2). Each of ABCD1 and 
GJC2 showed four novel variants. Following genes had each two novel variants: ASPA, FUCA, GALC, HEXA, 
L2HGDH and MLC1 (Table 2). The variants were classified according to ACMG guideline; 11 variants met the 
criteria for being pathogenic, 17 and 10 variants were likely pathogenic and VUS, respectively.
Discussion
Genetic diagnosis of childhood leukodystrophies is rapidly increasing throughout the past years in Iran and 
worldwide; approximately, 30 leukodystrophies and more that 60 disorders have been classified as genetic 
 leukoencephalopathies4. This study provides a comprehensive spectrum of leukodystrophies and other genetic 
leukoencephalopathies in Iran as referred to a tertiary pediatric center. Totally, 35 types of leukodystrophies were 
determined in the studied population. Based on pattern of brain MRI and single gene analysis, approximately 
69% (74 of 108) of the referred patients were confirmed by direct Sanger sequencing. Clinical diagnosis reduced 
the number of genes to be evaluated. Panel based analysis also confirmed leukodystrophies in 90% (40 of 44) 
of the cases. Our diagnostic rate of panel-based analysis was comparable to other  studies6. Four patients were 
No Name of disease
Alternative 
designation, 
abbreviation MIM # Gene Location of protein No of families (%)
Genetic testing
PhenotypesSingle gene WES













problem:2, AG: 2, Sei-
zure:2, MR:2, DD:1
25 Mucopolysaccharido-sis type IIIB MPS IIIB 609701 NAGLU Lysosome 1 (0. 9) 0 1
coarse facial feature, 
macrocephaly
26 Cockayne Syndrome CS 609413 ERCC6 Nucleus 1 (0. 9) 0 1 Microcephaly, AG, MR/R
27 Biotinidase deficiency BTD 253260 BTD Extracellular 1 (0. 9) 1 0 Seizure
28 L-2-hydroxyglutaric aciduria L-2-HGA 236792 L2HGDH Mitochondrion 3 (2. 6) 2 1
Hypotonia:1, Mac-
rocephaly:1, speech 
problem: 1, tremor: 
1, AG: 1, Seizure: 1, 
DD: 3, LD:1, Mental 
retardation:3




30 Mitochondrial DNA depletion syndrome 5 MDDS5 612073 SUCLA2 Mitochondrion 1 (0. 9) 0 1 Dystonia, R, DD













complex I deficiency, 
nuclear type 5





complex I deficiency, 
nuclear type 3




bly factor 1 deficiency
MCIID 252011 SDHAF1 Mitochondrion 1 (0. 9) 0 1 Speech problem, walk-ing problem, R
Total 114 (75) 74 (49%) 40 (26%)
Table 1.  The distribution of the leukodystrophies and genetic leukoencephalopathies based on single 
gene analysis and WES/panel based gene sequencing in 114 positive patients in the studied population. 
DD: Developmental delay; LD: learning difficulties; CI: Cognitive impairment; MR/R: Motor regression/
retardation; MD: motor delay, MD; AG: Abnormal gait; ER: Endoplasmic reticulum.
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genetically undiagnosed with panel-based/WES studies and WGS is needed to define the causes. Consequently, 
we had 25% (38 of 152) unsolved genetic cases and the diagnostic rate was 75% (114 of 152) of leukodystrophies 
and genetic leukoencephalopathies in the study. Various novel variants identified, show that a high rate of allelic 
heterogeneity exists among our patients. A specific composition of population living in Iran complicates this 
picture; different ethnicities with specific cultural customs demand to run more specific investigations on each 
population.
MLD was the most common cause of leukodystrophies in our  population9. The next diseases were CD, TSD, 
PMLD, X-ALD and then MLC. MLC is the most common (6 of 23) among Turk patients while PMLD may be 
common among Arab population in our study. Moreover, ten common diseases of this study, compromise 70% 
of all recognized patients (80 of 114) (Table 1). A recent study showed that peroxisomal disorders are identified 
to be common. Although other common disorders including Aicardi Goutières Syndrome, TUBB4A-related 
leukodystrophy, POLR3-related Leukodystrophy and Pelizaeus–Merzbacher Disease were not found in our study 
with a high  frequency10. ABCD1 had the highest relative frequency in their study while ARSA was the most 
common in our population.
Clinically, we had unsolved cases due to variable phenotypic features or overlapping neurological mani-
festations which were candidates of gene-panel and/or WES analysis. Despite we had patients with no genetic 
diagnosis even though they had undergone panel-based analysis. This could be due to intronic variants, copy 
number variations, unknown gene defects, and multigenic effect. Therefore, more genetic analysis should be 
performed for these cases and they could benefit from reanalysis of exome sequencing data, genome sequencing 
and transcriptomics. For rare diseases genetic analysis, NGS may unravel more genes relating to leukodystrophies 
in patients with unsolved  genetics6,11.
Lysosomal diseases had 43% incidence in our studied population which could be managed at earlier age of 
diagnosis. Individuals with known causal variants benefit from unexpected clinical presentations, prognosis, 
palliative treatment and avoiding unnecessary treatments. Hematopoietic stem cell transplantation (HSCT) has 
been used for lysosomal storage  diseases7. Some of our patients might potentially have benefitted from HSCT at 
early stages of the disease. However, patients’ follow up for HSCT is out of the scope of this study.
Some have an ethnic-specific distribution, e. g. TSD in Ashkenazi Jewish population, GM1 gangliosidosis 
in Rudari isolate and MLD in Western Navajo  Nation12. MLD patients were from western part of  Iran9. Four of 
our TSD patients were from northern parts of Iran.
The peroxisomal disorders, as a heterogeneous group, occur due to a defect in function (e. g. X-ALD) and 
biogenesis (e. g. Zellweger spectrum) of peroxisomes. X-ALD is the most common peroxisomal disorder caused 
by mutation in the ABCD1 gene co-expressed with HSD17B4 gene. Patients with X-ALD could benefit from 
 HSCT13 or hematopoietic stem-cell gene  therapy8.
CD is the second frequent disease in our study. It is the most common disease during infancy and has been 
observed mainly in Ashkenazi Jews while in our study patients were from various ethnicities. Various experimen-
tal therapies for Canavan patients are under  investigation14. Patients with known genetic etiology may benefit 
from such experimental therapies.
PMLD is responsible for 8% of hypomyelinating leukodystrophy  patients15. In this study 7% of the patients 
had the disease. In addition to GJC2, mutations in other genes such as a Myelin-associated glycoprotein (MAG) 
gene have been reported to cause  PMLD16. GJC2 is co-expressed with PLP1 and interacts with products of 
FAM1256A, POLR3A and EIF2B5 genes. Our results highlighted that PMLD may have a higher frequency than 
Figure 1.  (A) The distribution of the most common diagnosed leukodystrophies (86 of 114 patients) in our 
studied patients include 19 of 86 (22%) MLD, 12 CD, 11 TSD, 8 X-ALD, 8 PMLD1, 7 MLC, 6 SHS, 5 KD, 4 
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PMD in our population especially in Arab and Fars ethnicities. Also, six of MLC patients were from Turk ethnic-
ity; it may be a common disorder and limit to specific ethnicity e. g. from Turkey.
11% of patients diagnosed with mitochondrial genetic leukoencephalopathies; Leigh syndrome and L-2-HGA 
accounted for 4 and 3 of them, respectively. Leigh spectrum was due to SURF1. Also, it was due to NDUFS1, 
NDUFS7 and SDHAF1 genes. L2HGDH encoding mitochondrial L-2-hydroxyglutarate dehydrogenase may be 
common in our ethnicities. The mechanism of leukodystrophy is very complicated and there may be proteins 
involved in disease progress which show overlapping phenotype but have no or unknown interaction with each 
other.
Analysis of founder effect and hotspot mutations. Ancestral or founder effect or a genetic signature 
within an ethnicity usually leads to a high frequency and homozygosity of a mutation in that cohort; in contrast, 
if a specific mutation is distributed uniformly among many ethnicities, it is known as a mutational hotspot. Hap-
lotype analysis is used to define recognized that a mutation is a hotspot or a founder one. The studied mutations 
of ABCD1 (c. 1415_1416delAG), ASPA(c. 634 + 1G > T and c. 237_238insA) and HEXA (c. 1528C > T) show a 
wide distribution around the  world17–20; especially c. 634 + 1G > T in ASPA gene has been reported from Turkey 
for the first time and we found it in patients from Fars, Afghani, Lur and Arab  ethnicities18. These mutations are 
Figure 2.  The flow chart of patients undergoing different genetic testing in this cohort and identified 
leukodystrophies. Fifty of 114 patients were diagnosed as lysosomal disorders (29 lysosomal LD and 21 
lysosomal gLE). Forty-one patients genetically were confirmed for MLD, TSD, SHS and KD. Eleven patients 
were diagnosed as peroxisomal disorders which eight of them were X-ALD. One patient had peroxisomal 
single enzyme beta oxidation deficiency, and two patients had peroxisomal biogenesis disorders. Forty patients 
diagnosed as errors of intermediary metabolism, consisted of 12 CD, 8 PMLD and 7 MLC (Table 1). CD as 
the most common degenerative cerebral diseases, due to abnormal amino acid/organic acid metabolism, 
accounted for the second most common disease in our population. PMD and PMLD are disorders of myelin 
genes. 4 patients had vWM, 2 patients with hypomyelination-hypogonadotropic-hypogonadism-hypodontia, 
1 hypomyelination and congenital contract, 1 PMD, 1 AxD, 1 infantile neuroaxonal dystrophy/atypical 
neuroaxonal dystrophy, 1 hypomyelination leukodystrophy 9 (HLD9, MIM 616140), 1 Cockayne syndrome 
CS, MIM 133540), and 1 biotinidase deficiency. Thirteen patients diagnosed with mitochondrial genetic 
leukoencephalopathies; Leigh syndrome and L-2-HGA accounted for 4 and 3 of them, respectively.
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considered as hotspots i.e. they are mutated in many populations. Contrarily, mutations of MLC1 (c. 177 + 1G > T 
and c. 449_455delTCC TGC T) may have ancestors in Turk population. Especially, the c. 449_455delTCC TGC T 
variant was observed in three families; it may be originated from a founder ancestor in Turk population and it 
previously has been reported from  Turkey21.
Challenges and limitations. We have not included all the affected patients in our registry, only the 
patients referred to our center for genetic testing were accounted in this study. In addition, Children’s Hospital 
is a tertiary center in Tehran and some patients around the country may have not been registered and/or died 
previously before registration. Therefore, a multicenter registry is needed. The incidence of the disease in this 
part of the world may be different due to consanguineous marriages. Ethnical background had higher incidence 
in Fars and Turk; however, the population of these ethnicities is also high in Iran.
Table 2.  Novel variants identified in this study. DC: disease causing, PD: probably damaging, 
Hom = homozygous, B = benign, NA = not available.
No Nucleotide change AA change Gene no. of patients Zygosity ACMG MutationTaster Polyphen-2 CADD
1 c. 2099A > C p. Asn700Thr POLR3B 1 Hom Likely pathogenic (2) DC PD 0. 998 27. 2
2 c. 786A > C p. Gln262Asp SLC17A5 1 Hom Likely pathogenic (2) DC PD 1. 000 24. 2
3 c. 904_905delinsAT p. Glu302Met ABCD1 1 Hemi Likely pathogenic (2) DC NA 26. 8
4 c. 1628C > G p. Pro543Arg ABCD1 1 Hemi Likely pathogenic (2) DC PD 1. 000 23. 8
5 c. 2002A > G + c. 1021G > T p. Thr668Ala + p. Ala-341Ser ABCD1 1 Hemi
Likely pathogenic (2)
Likely pathogenic (2) DC PD 0. 761 23. 7
6 c. 839G > C p. Arg280Pro ABCD1 1 Hemi Likely pathogenic (2) DC PD 1. 000 32
7 c. 233C > A p. Ser78Ter RNASET2 1 Hom Pathogenic (1) DC NA 36
8 c. 437_449delCTC TGG CTC CAC T p. Ser146TyrfsX7 ASPA 1 Hom Pathogenic (1) DC NA 34
9 c. 359C > T p. Ser120Phe ASPA 1 Hom Uncertain significance (3) DC PD 1. 000 29. 1
10 c. 866G > A p. ser289Ile EIF2B4 1 Hom Uncertain significance (3) DC B 0. 002 22. 9
11 c. 422G > T p. Gly141Val FUCA1 1 Hom Likely pathogenic (2) DC PD 1. 000 28. 8
12 c. 82delG p. Val28CysfsX105 FUCA1 1 Hom Pathogenic (1) DC NA 16. 62
13 c. 830G > A p. Ser277Asn GALC 1 Hom Likely pathogenic (2) DC PD 0. 946 23. 9
14 c. 1942A > T p. Lys648Ter GALC 1 Hom Uncertain significance (3) DC NA 36
15 c. 408 + 1G > C – L2HGDH 1 Hom Pathogenic (1) DC NA 34
16 c. 1213A > G p. Arg405Gly L2HGDH 1 Hom Uncertain significance (3) DC PD 1. 000 22. 7
17 c. 183C > A p. Cys61Ter MLC1 1 Hom Pathogenic (1) DC NA 37
18 c. 819C > G p. Phe273Leu MLC1 1 Hom Uncertain significance (3) DC PD 0. 990 24. 1
19 c. 571_572insC p. Thr195AspfsX69 GJC2 1 Hom Pathogenic (1) DC NA 17. 5
20 c. 118G > C p. Ala40Pro GJC2 2 Hom Likely pathogenic (2) DC PD 1. 000 24. 6
21 c. 733 T > A p. Cys245Ser GJC2 2 Hom Likely pathogenic (2) DC PD 1. 000 25. 1
22 c. 883C > T p. Gln295Ter GJC2 1 Hom Likely pathogenic (2) DC NA 38
23 c. 529_531delAAA p. Lys177del PEX13 1 Hom Pathogenic (1) DC NA 22. 2
24 c. 345C > G p. Ile115Met PEX14 1 Het Uncertain significance (3) DC PD 0. 999 23. 5
25 c. 655_657delATT p. Ile219del HEXB 1 Hom Pathogenic (1) DC NA 20. 3
26 c. 754C > T p. Arg252Cys HEXA 1 Hom Likely pathogenic (2) DC PD 1. 000 30
27 c. 1147-1G > T – HEXA 1 Hom Pathogenic (1) DC NA 28. 3
28 c. 16C > T p. Arg6Cys PLA2G6 1 Hom Uncertain significance (3) DC PD 0. 994 25
29 c. 416 T > A p. Leu139Gln GLB1 1 Hom Likely pathogenic (2) DC PD 1. 000 29. 3
30 c. 997G > T p. Asp333Tyr SUCLA2 1 Hom Likely pathogenic (2) DC PD 1. 000 31
31 c. 3482 + 6C > T – POLG 1 Hom Uncertain significance (3) DC NA 9. 6
32 c. 29A > C p. Gln10Pro SDHAF1 1 Hom Uncertain significance (3) DC PD 1. 000 27
33 c. 808_812delGAGCA p. Glu270SerfsX20 SURF1 1 Hom Pathogenic (1) DC NA 35
34 c. 362 + 5G > A - PPT1 1 Hom Pathogenic (1) DC NA 21. 9
35 c. 659A > C p. Tyr220Ser CLN6 1 hom Uncertain significance (3) DC PD 0. 986 32
36 c. 392C > A p. Thr131Lys HSD17B4 1 Hom Likely pathogenic (2) DC PD 0. 985 33
37 c. 1285G > A p. Val429Met NDUFS1 1 Hom Likely pathogenic (2) DC PD 0. 971 28. 8
38 c. 415G > A p. Asp139Asn NDUFS7 1 Hom Likely pathogenic (2) DC PD 1. 000 25. 5
8
Vol:.(1234567890)
Scientific Reports |         (2021) 11:3231  | https://doi.org/10.1038/s41598-021-82778-0
www.nature.com/scientificreports/
Conclusion
In conclusion, five common disorders are responsible for more than fifty percent of leukodystrophies in this 
region. Considering Iran as the crossroad of the Middle East is composed of more than 15  ethnicities22, it 
may reflect the distribution of leukodystrophies in the Middle East especially its neighboring populations. For 
instance, PMDL may be common among Arab countries while MLC may have a high frequency in Turkish 
countries. Genetic analysis provides diagnostic confirmation of the disease, and physicians are allowed for prog-
nosis and management of patients and affected families. Genetic testing following counseling decreases further 
worry of the family about the diagnosis and further costs. The mortality rate in affected families is very high 
and it underscores the necessity of genetic testing in the country. Moreover, this study provides information to 
help for future therapeutic planning’s in the country. This will allow a diagnosis at earlier stages of the disease, 
reduce the burden of uncertainty and costs, and will provide the basis for genetic counseling and family planning.
Methods
Patients. Clinically diagnosed patients with white matter deterioration were enrolled in the study from dif-
ferent ethnicity of Iran between 2016 and 2019. Clinical characteristics of leukodystrophies and leukoencepha-
lopathies were approved by pediatric neurologists. Demographic data, medical and family history, physical eval-
uations, neurological examinations, magnetic resonance imaging (MRI), and laboratory testing of each patient 
were recorded for each patient. The study was approved by the ethical committee of Iran University of Medical 
Sciences. Informed consent was obtained for genetic testing from the parents of patients. All experimental pro-
tocols were approved by Growth and Development Research Center, Tehran University of Medical Sciences and 
performed in accordance with relevant guidelines and regulations.
Study strategy. Single gene analysis based on clinical diagnosis. Patients with a strongly suspected cause of 
their leukodystrophy were genetically analyzed for the respective relevant gene. These studies included the genes 
of metachromatic leukodystrophy (MLD), Canavan disease (CD, MIM 271900), X-linked adrenoleukodystro-
phy (X-ALD, MIM 300100), Alexander disease (AxD), Tay-Sachs disease (TSD, MIM 272800), Sandhoff disease 
(SHS, MIM 268800), Krabbe disease (KD), megalencephalic leukodystrophy with subcortical cysts (MLC, MIM 
604004), Sialic acid storage disease (SD, MIM 269920), Pelizaeus–Merzbacher disease (PMD, MIM 312080), and 
Pelizaeus–Merzbacher-like disease type 1 (PMLD1, MIM 608804).
DNA was extracted and amplified by using specific designed primers for coding regions (exons and 
exon–intron boundaries). The selected genes associated with leukodystrophy were classified to inherited auto-
somal recessive diseases: ARSA(NM_000487. 5; 605908 ), GALC(NM_000153. 3; 606890), MLC1(NM_015166. 
3; 605908), BTD(NM_000060. 4; ), GFAP(NM_002055. 4; 137780), GJC2(NM_020435. 3; 608803), 
HEXB(NM_000521. 3; MIM 606873), HEXA(NM_000520. 5; MIM 606869), ASPA(NM_000049. 2; 608034) 
and SLC17A5(NM_012434. 5 MIM, 604322), FAM126A(NM_032581. 3; 610531), and X-linked recessive 
ABCD1(NM_000033. 3; 300371), and PLP1(NM_001128834. 2; 300401), respectively. Direct sequencing was 
performed by BigDye termination method ABI 3500 (Applied BioSystems, US).
Next generation sequencing: gene‑panel and whole exome sequencing (WES). Those patients (n = 41) with indefi-
nite clinical diagnosis or overlapping symptoms and neurological findings underwent panel gene analysis to 
detect the genetic cause. Panel based gene analysis was performed for cases for 59 genes involving in leukodys-
trophy, leukoencephalopathy and vanishing matter white disease (Supplementary Table 1). The coding regions 
and exon–intron boundaries of the genes were enriched using NimbleGen kit (NimbleGen, Roche, Basel, Swit-
zerland). Sequencing analysis was performed by Illumina, Hiseq2000 (Illumina, San Diego, California, USA). 
Reads were aligned using Burrows–Wheeler Aligner (BWA) on reference genome (hg19), called by SAMTools 
and annotated by GATK and ANNOVAR. Based on, 1000Genome and dbSNP database variant were selected 
for analysis. Coverage of target region with at least depth of 30X was 99%. In addition, WES was only performed 
with an average coverage depth of ≈100X for three patients. Sanger sequencing was done for the candidate vari-
ants in the affected families.
Variant categories. The sequence data were compared with public databases and filtered to find out the can-
didate variants according to published pipelines. The candidate variants were categorized as the previously 
reported pathogenic variants and novel variants. ACMG guideline criteria were used to interpret novel variants 
and classify  them23.
In silico analyses. Pathogenic effect. According to HGVS (http://varno men.hgvs.org/.hgvs.org/), novel 
variants were named as missense, nonsense, splice site, intronic, regulatory and indel. The following software 
tools were applied to predict the pathogenic effects of novel variants: polymorphism phenotyping (PolyPhen-
2v2.1)24, combined annotation dependent depletion (CADD)25 and  MutationTaster26.
Ethics approval and patients’ consent. Ethical approval was supported by Growth and development 
research center, Tehran University of Medical Sciences ID number 98–02-80–43,432 and Iran University of 
Medical Sciences (IR.IUMS.REC.1399.817). Informed consent was obtained from the parents of patients.
Consent for publication. All contributing authors have read the manuscript and given their consent for 
the publication of this study.
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